YORKSHIRE_PHARMACEUTICAL_ - Accounts

Company Registration No. 00407369 (England and Wales)
YORKSHIRE PHARMACEUTICAL INDUSTRIES LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019
PAGES FOR FILING WITH REGISTRAR
YORKSHIRE PHARMACEUTICAL INDUSTRIES LIMITED
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 6
YORKSHIRE PHARMACEUTICAL INDUSTRIES LIMITED
BALANCE SHEET
AS AT
31 MARCH 2019
31 March 2019
- 1 -
2019
2018
Notes
£
£
£
£
Fixed assets
Investments
3
163,611
179,971
Current assets
Debtors
4
70,123
70,123
Creditors: amounts falling due within one year
5
(63,793)
(63,389)
Net current assets
6,330
6,734
Total assets less current liabilities
169,941
186,705
Capital and reserves
Called up share capital
6
500
500
Other reserves
12,081
12,081
Profit and loss reserves
7
157,360
174,124
Total equity
169,941
186,705

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 26 November 2019 and are signed on its behalf by:
Sir M A Heller
Director
Company Registration No. 00407369
YORKSHIRE PHARMACEUTICAL INDUSTRIES LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2019
- 2 -
Share capital
Other reserves
Profit and loss reserves
Total
£
£
£
£
Balance at 1 April 2017
500
12,081
139,481
152,062
Year ended 31 March 2018:
Profit and total comprehensive income for the year
-
-
34,643
34,643
Balance at 31 March 2018
500
12,081
174,124
186,705
Year ended 31 March 2019:
Loss and total comprehensive income for the year
-
-
(16,764)
(16,764)
Balance at 31 March 2019
500
12,081
157,360
169,941
YORKSHIRE PHARMACEUTICAL INDUSTRIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2019
- 3 -
1
Accounting policies
Company information

Yorkshire Pharmaceutical Industries Limited is a private company, limited by shares and incorporated in England and Wales. The registered office is Hart Shaw, Europa Link, Sheffield Business Park, Sheffield, S9 1XU.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2
Turnover
Turnover represents dividends received net of any tax credits.
1.3
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

Listed investments are stated at market value.

 

Dividends are accounted for in the Profit and loss account as and when received.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.4
Cash at bank and in hand

Cash at bank and in hand are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

YORKSHIRE PHARMACEUTICAL INDUSTRIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2019
1
Accounting policies
(Continued)
- 4 -
1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

1.6
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.7
Derivatives

Derivatives are initially recognised at fair value at the date a derivative contract is entered into and are subsequently remeasured to fair value at each reporting end date. The resulting gain or loss is recognised in profit or loss immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in profit or loss depends on the nature of the hedge relationship.

 

A derivative with a positive fair value is recognised as a financial asset, whereas a derivative with a negative fair value is recognised as a financial liability.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was 4 (2018: 4).

YORKSHIRE PHARMACEUTICAL INDUSTRIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2019
- 5 -
3
Fixed asset investments
2019
2018
£
£
Investments
163,611
179,971
Movements in fixed asset investments
Shares in group undertakings and participating interests
Other investments other than loans
Total
£
£
£
Cost or valuation
At 1 April 2018
20
179,951
179,971
Valuation changes
-
(16,360)
(16,360)
At 31 March 2019
20
163,591
163,611
Carrying amount
At 31 March 2019
20
163,591
163,611
At 31 March 2018
20
179,951
179,971
4
Debtors
2019
2018
Amounts falling due within one year:
£
£
Other debtors
70,123
70,123
5
Creditors: amounts falling due within one year
2019
2018
£
£
Bank loans and overdrafts
29,223
28,865
Other creditors
33,850
33,850
Accruals
720
674
63,793
63,389
6
Called up share capital
2019
2018
£
£
Ordinary share capital
Issued and fully paid
500 Ordinary shares of £1 each
500
500
YORKSHIRE PHARMACEUTICAL INDUSTRIES LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2019
- 6 -
7
Profit and loss reserves

Included in profit and loss reserves are non-distributable reserves of £72,744 (2018 - £89,104). These reserves relate to the increase in fair value of the investment property and listed investments, less any directly attributable deferred tax liability.

8
Audit report information

As the income statement has been omitted from the filing copy of the financial statements the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006:

The auditor's report was unqualified.

The senior statutory auditor was Martin McDonagh.
The auditor was Hart Shaw LLP.
2019-03-312018-04-01false10 December 2019CCH SoftwareCCH Accounts Production 2019.301No description of principal activityThis audit opinion is unqualifiedSir M A HellerLady M HellerMr J A HellerMr A R HellerA R Heller004073692018-04-012019-03-31004073692019-03-31004073692018-03-3100407369core:CurrentFinancialInstruments2019-03-3100407369core:CurrentFinancialInstruments2018-03-3100407369core:ShareCapital2019-03-3100407369core:ShareCapital2018-03-3100407369core:OtherMiscellaneousReserve2019-03-3100407369core:OtherMiscellaneousReserve2018-03-3100407369core:RetainedEarningsAccumulatedLosses2019-03-3100407369core:RetainedEarningsAccumulatedLosses2018-03-3100407369bus:Director12018-04-012019-03-3100407369core:RetainedEarningsAccumulatedLosses2017-04-012018-03-31004073692017-04-012018-03-3100407369core:RetainedEarningsAccumulatedLosses2018-04-012019-03-3100407369bus:PrivateLimitedCompanyLtd2018-04-012019-03-3100407369bus:SmallCompaniesRegimeForAccounts2018-04-012019-03-3100407369bus:FRS1022018-04-012019-03-3100407369bus:Audited2018-04-012019-03-3100407369bus:Director22018-04-012019-03-3100407369bus:Director32018-04-012019-03-3100407369bus:Director42018-04-012019-03-3100407369bus:CompanySecretary12018-04-012019-03-3100407369bus:FullAccounts2018-04-012019-03-31xbrli:purexbrli:sharesiso4217:GBP